한글목차

인간 마이크로바이옴 치료제 시장은 2022-20271년에 7억 3,295만 달러, 예측 기간 중 CAGR은 30.11%로 성장할 것으로 예측되고 있습니다.

인간 마이크로바이옴 치료제 시장의 전체적인 분석, 시장 규모·예측, 동향, 시장 촉진요인·촉진요인, 과제, 약 25개 벤더를 다룬 벤더 분석 등을 제공합니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공하고 있습니다. 시장은 만성질환의 유병률 증가, 인간 마이크로바이옴 치료제 시장에서의 왕성한 파이프라인, 건강 장애에 대한 기존 치료법의 부작용에 의해 촉진되고 있습니다.

향후 수년간 인간 마이크로바이옴 치료제 시장의 성장을 촉진하는 주요 이유의 하나로 신규 치료제 개발을 위한 산학 제휴의 증가를 들고 있습니다. 또한 인간 마이크로바이옴 치료제에 대한 투자의 증가 및 인간 마이크로바이옴 치료제 시장에서 파트너십의 증가가 시장의 큰 수요로 연결됩니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 에코시스템

제3장 시장 규모

• 시장의 정의
• 시장 부문 분석
• 시장 규모 2022
• 시장 전망 2022-2027

제4장 시장 규모 실적

• 세계의 인간 마이크로바이옴 치료제 시장 2017-2021
• 제품 부문 분석 2017-2021
• 용도별 부문 분석 2017-2021
• 지역별 부문 분석 2017-2021
• 국가별 부문 분석 2017-2021

제5장 Five forces 분석

• Five Forces 요약
• 구매자의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁의 위협
• 시장 현황

제6장 시장 세분화 : 제품별

• 시장 부문
• 비교 : 제품별
• 프로바이오틱스 : 시장 규모와 예측 2022-2027
• 프리바이오틱스 : 시장 규모와 예측 2022-2027
• 의료용 식품 : 시장 규모와 예측 2022-2027
• 처방약 : 시장 규모와 예측 2022-2027
• 시장 기회 : 제품별

제7장 시장 세분화 : 용도별

• 시장 부문
• 비교 : 용도별
• 위장 장애 : 시장 규모와 예측 2022-2027
• 감염증 : 시장 규모와 예측 2022-2027
• 기타 : 시장 규모와 예측 2022-2027
• 시장 기회 : 용도별

제8장 고객 상황

• 고객 상황의 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측 2022-2027
• 유럽 : 시장 규모와 예측 2022-2027
• 아시아 : 시장 규모와 예측 2022-2027
• 세계의 기타 지역 : 시장 규모와 예측 2022-2027
• 미국 : 시장 규모와 예측 2022-2027
• 독일 : 시장 규모와 예측 2022-2027
• 프랑스 : 시장 규모와 예측 2022-2027
• 영국 : 시장 규모와 예측 2022-2027
• 일본 : 시장 규모와 예측 2022-2027
• 지역 상황별 시장 기회

제10장 촉진요인, 과제 및 동향

• 시장 촉진요인
• 시장이 해결해야 할 과제
• 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란의 상황
• 업계의 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• 4D pharma Plc
• BiomX Inc.
• Eligo Bioscience
• ENTEROME SA
• Evelo Biosciences Inc.
• Evogene Ltd.
• Ferring BV
• Finch Therapeutics Group Inc.
• Johnson and Johnson Services Inc.
• OptiBiotix Health Plc
• PureTech Health Plc
• Second Genome Therapeutics
• Seres Therapeutics Inc.
• Synlogic Inc.
• Takeda Pharmaceutical Co. Ltd.

제13장 부록

영문목차

The human microbiome therapeutics market is forecasted to grow by USD 732.95 mn during 2022-2027, accelerating at a CAGR of 30.11% during the forecast period. The report on the human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of chronic diseases, robust pipeline in human microbiome therapeutics market, and side effects of existing treatments for heath disorders.

Technavio's human microbiome therapeutics market is segmented as below:

By Product

• Probiotics
• Prebiotics
• Medical foods
• Prescription drugs

By Application

• Gastrointestinal disorders
• Infectious diseases
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increase in industry-academia collaboration for development of novel therapeutics as one of the prime reasons driving the human microbiome therapeutics market growth during the next few years. Also, increasing investments in human microbiome therapeutics and increasing partnerships in human microbiome therapeutics market will lead to sizable demand in the market.

The report on the human microbiome therapeutics market covers the following areas:

• Human microbiome therapeutics market sizing
• Human microbiome therapeutics market forecast
• Human microbiome therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human microbiome therapeutics market vendors that include 4D pharma Plc, BiomX Inc., Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc., Evogene Ltd., Ferring BV, Finch Therapeutics Group Inc., Flightpath Biosciences, Johnson and Johnson Services Inc., MaaT Pharma, Microbiotica Ltd., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., YSOPIA Bioscience, and Locus Biosciences Inc.. Also, the human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Application
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global human microbiome therapeutics market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on global human microbiome therapeutics market 2017 - 2021 ($ million)
• 4.2 Product Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
• 4.3 Application Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - Application Segment 2017 - 2021 ($ million)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
• 6.2 Comparison by Product
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product
• 6.3 Probiotics - Market size and forecast 2022-2027
• Exhibit 34: Chart on Probiotics - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Probiotics - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Probiotics - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Probiotics - Year-over-year growth 2022-2027 (%)
• 6.4 Prebiotics - Market size and forecast 2022-2027
• Exhibit 38: Chart on Prebiotics - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Prebiotics - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Prebiotics - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Prebiotics - Year-over-year growth 2022-2027 (%)
• 6.5 Medical foods - Market size and forecast 2022-2027
• Exhibit 42: Chart on Medical foods - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Medical foods - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Medical foods - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Medical foods - Year-over-year growth 2022-2027 (%)
• 6.6 Prescription drugs - Market size and forecast 2022-2027
• Exhibit 46: Chart on Prescription drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 47: Data Table on Prescription drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Chart on Prescription drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Prescription drugs - Year-over-year growth 2022-2027 (%)
• 6.7 Market opportunity by Product
• Exhibit 50: Market opportunity by Product ($ million)
• Exhibit 51: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Application

• 7.1 Market segments
• Exhibit 52: Chart on Application - Market share 2022-2027 (%)
• Exhibit 53: Data Table on Application - Market share 2022-2027 (%)
• 7.2 Comparison by Application
• Exhibit 54: Chart on Comparison by Application
• Exhibit 55: Data Table on Comparison by Application
• 7.3 Gastrointestinal disorders - Market size and forecast 2022-2027
• Exhibit 56: Chart on Gastrointestinal disorders - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Gastrointestinal disorders - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Gastrointestinal disorders - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Gastrointestinal disorders - Year-over-year growth 2022-2027 (%)
• 7.4 Infectious diseases - Market size and forecast 2022-2027
• Exhibit 60: Chart on Infectious diseases - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Data Table on Infectious diseases - Market size and forecast 2022-2027 ($ million)
• Exhibit 62: Chart on Infectious diseases - Year-over-year growth 2022-2027 (%)
• Exhibit 63: Data Table on Infectious diseases - Year-over-year growth 2022-2027 (%)
• 7.5 Others - Market size and forecast 2022-2027
• Exhibit 64: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 67: Data Table on Others - Year-over-year growth 2022-2027 (%)
• 7.6 Market opportunity by Application
• Exhibit 68: Market opportunity by Application ($ million)
• Exhibit 69: Data Table on Market opportunity by Application ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 71: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibit 72: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 73: Chart on Geographic comparison
• Exhibit 74: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.9 France - Market size and forecast 2022-2027
• Exhibit 99: Chart on France - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on France - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on France - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on France - Year-over-year growth 2022-2027 (%)
• 9.10 UK - Market size and forecast 2022-2027
• Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)
• 9.11 Japan - Market size and forecast 2022-2027
• Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 111: Market opportunity By Geographical Landscape ($ million)
• Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 113: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 115: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 116: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 117: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 118: Matrix on vendor position and classification
• 12.3 4D pharma Plc
• Exhibit 119: 4D pharma Plc - Overview
• Exhibit 120: 4D pharma Plc - Product / Service
• Exhibit 121: 4D pharma Plc - Key offerings
• 12.4 BiomX Inc.
• Exhibit 122: BiomX Inc. - Overview
• Exhibit 123: BiomX Inc. - Product / Service
• Exhibit 124: BiomX Inc. - Key offerings
• 12.5 Eligo Bioscience
• Exhibit 125: Eligo Bioscience - Overview
• Exhibit 126: Eligo Bioscience - Product / Service
• Exhibit 127: Eligo Bioscience - Key offerings
• 12.6 ENTEROME SA
• Exhibit 128: ENTEROME SA - Overview
• Exhibit 129: ENTEROME SA - Product / Service
• Exhibit 130: ENTEROME SA - Key offerings
• 12.7 Evelo Biosciences Inc.
• Exhibit 131: Evelo Biosciences Inc. - Overview
• Exhibit 132: Evelo Biosciences Inc. - Product / Service
• Exhibit 133: Evelo Biosciences Inc. - Key offerings
• 12.8 Evogene Ltd.
• Exhibit 134: Evogene Ltd. - Overview
• Exhibit 135: Evogene Ltd. - Business segments
• Exhibit 136: Evogene Ltd. - Key offerings
• Exhibit 137: Evogene Ltd. - Segment focus
• 12.9 Ferring BV
• Exhibit 138: Ferring BV - Overview
• Exhibit 139: Ferring BV - Product / Service
• Exhibit 140: Ferring BV - Key offerings
• 12.10 Finch Therapeutics Group Inc.
• Exhibit 141: Finch Therapeutics Group Inc. - Overview
• Exhibit 142: Finch Therapeutics Group Inc. - Product / Service
• Exhibit 143: Finch Therapeutics Group Inc. - Key offerings
• 12.11 Johnson and Johnson Services Inc.
• Exhibit 144: Johnson and Johnson Services Inc. - Overview
• Exhibit 145: Johnson and Johnson Services Inc. - Business segments
• Exhibit 146: Johnson and Johnson Services Inc. - Key news
• Exhibit 147: Johnson and Johnson Services Inc. - Key offerings
• Exhibit 148: Johnson and Johnson Services Inc. - Segment focus
• 12.12 OptiBiotix Health Plc
• Exhibit 149: OptiBiotix Health Plc - Overview
• Exhibit 150: OptiBiotix Health Plc - Product / Service
• Exhibit 151: OptiBiotix Health Plc - Key offerings
• 12.13 PureTech Health Plc
• Exhibit 152: PureTech Health Plc - Overview
• Exhibit 153: PureTech Health Plc - Business segments
• Exhibit 154: PureTech Health Plc - Key offerings
• Exhibit 155: PureTech Health Plc - Segment focus
• 12.14 Second Genome Therapeutics
• Exhibit 156: Second Genome Therapeutics - Overview
• Exhibit 157: Second Genome Therapeutics - Product / Service
• Exhibit 158: Second Genome Therapeutics - Key offerings
• 12.15 Seres Therapeutics Inc.
• Exhibit 159: Seres Therapeutics Inc. - Overview
• Exhibit 160: Seres Therapeutics Inc. - Product / Service
• Exhibit 161: Seres Therapeutics Inc. - Key offerings
• 12.16 Synlogic Inc.
• Exhibit 162: Synlogic Inc. - Overview
• Exhibit 163: Synlogic Inc. - Product / Service
• Exhibit 164: Synlogic Inc. - Key offerings
• 12.17 Takeda Pharmaceutical Co. Ltd.
• Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 169: Inclusions checklist
• Exhibit 170: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 171: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 172: Research methodology
• Exhibit 173: Validation techniques employed for market sizing
• Exhibit 174: Information sources
• 13.5 List of abbreviations
• Exhibit 175: List of abbreviations